Renal cell carcinoma (advanced) - axitinib [ID518]: evaluation report
Table of Contents
01. NICE's response to comments on the Appraisal Consultation Document (ACD)
02. [Consultee/Commentator] comments on the ACD - Pfizer
03. [Consultee/Commentator] comments on the ACD - Kidney Cancer UK
04. [Consultee/Commentator] comments on the ACD - Royal College of Physicians
05. Clinical expert comments on the ACD - Hawkins
06. Public comments on the ACD received via the NICE website
07. ERG Response following specific questions from NICE provided by Kleijnen Systematic Reviews
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
Renal cell carcinoma (advanced) - axitinib [ID518]: evaluation report
16 December 2014 (1.66 Mb 15 sec) |
This page was last updated: 11 December 2014